1. Home
  2. PBT vs ACRS Comparison

PBT vs ACRS Comparison

Compare PBT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Permian Basin Royalty Trust

PBT

Permian Basin Royalty Trust

N/A

Current Price

$34.84

Market Cap

1.0B

Sector

Energy

ML Signal

N/A

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.92

Market Cap

868.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PBT
ACRS
Founded
1980
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
868.5M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
PBT
ACRS
Price
$34.84
$3.92
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $10.18
AVG Volume (30 Days)
100.6K
★ 3.6M
Earning Date
11-11-2026
11-05-2026
Dividend Yield
★ 0.81%
N/A
EPS Growth
N/A
★ 69.01
EPS
★ N/A
N/A
Revenue
N/A
★ $1,683,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$57.37
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.25
$1.74
52 Week High
$37.00
$6.60

Technical Indicators

Market Signals
Indicator
PBT
ACRS
Relative Strength Index (RSI) 61.97 33.30
Support Level $32.38 $3.16
Resistance Level $35.46 $4.63
Average True Range (ATR) 1.22 0.41
MACD 0.17 -0.15
Stochastic Oscillator 96.31 28.38

Price Performance

Historical Comparison
PBT
ACRS

About PBT Permian Basin Royalty Trust

Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: